IRIS
GALLUZZO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.878
AS - Asia 3.366
EU - Europa 2.051
Continente sconosciuto - Info sul continente non disponibili 698
SA - Sud America 431
AF - Africa 51
OC - Oceania 7
Totale 20.482
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.738
SG - Singapore 1.554
IT - Italia 585
CN - Cina 488
RU - Federazione Russa 360
BD - Bangladesh 348
BR - Brasile 344
HK - Hong Kong 339
VN - Vietnam 245
IE - Irlanda 238
DE - Germania 206
FR - Francia 131
GB - Regno Unito 111
JP - Giappone 109
FI - Finlandia 95
CA - Canada 78
IN - India 73
UA - Ucraina 72
NL - Olanda 54
ID - Indonesia 46
SE - Svezia 46
KR - Corea 35
AR - Argentina 34
PL - Polonia 33
ES - Italia 29
AT - Austria 28
MX - Messico 20
CO - Colombia 19
PK - Pakistan 17
TR - Turchia 16
ZA - Sudafrica 16
CH - Svizzera 13
IQ - Iraq 12
JM - Giamaica 12
EC - Ecuador 11
MA - Marocco 10
PH - Filippine 10
MY - Malesia 9
PY - Paraguay 9
CL - Cile 8
NP - Nepal 8
LT - Lituania 7
PT - Portogallo 7
UZ - Uzbekistan 7
AU - Australia 6
BE - Belgio 6
RO - Romania 6
SA - Arabia Saudita 6
GR - Grecia 5
HN - Honduras 5
IR - Iran 5
KG - Kirghizistan 5
CR - Costa Rica 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
KE - Kenya 4
KZ - Kazakistan 4
TH - Thailandia 4
TN - Tunisia 4
TW - Taiwan 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
EG - Egitto 3
ET - Etiopia 3
EU - Europa 3
GT - Guatemala 3
IL - Israele 3
LB - Libano 3
MN - Mongolia 3
PA - Panama 3
SI - Slovenia 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
GE - Georgia 2
JO - Giordania 2
SC - Seychelles 2
SN - Senegal 2
AD - Andorra 1
AW - Aruba 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BZ - Belize 1
CG - Congo 1
CU - Cuba 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GP - Guadalupe 1
HR - Croazia 1
HU - Ungheria 1
KY - Cayman, isole 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
NI - Nicaragua 1
NO - Norvegia 1
Totale 19.782
Salva come PNG Salva come JPEG
Città #
Wilmington 3.187
Houston 2.946
Woodbridge 1.607
Singapore 760
Fairfield 687
Ashburn 627
San Jose 570
Council Bluffs 376
Hong Kong 335
Seattle 334
Chandler 302
Cambridge 255
Dublin 219
Ann Arbor 191
Dallas 176
Beijing 164
The Dalles 158
Medford 152
Santa Clara 135
Rome 113
New York 108
Los Angeles 103
Tokyo 96
Dearborn 93
Ho Chi Minh City 81
Lawrence 72
Buffalo 68
Munich 68
Hanoi 66
Lauterbourg 63
Moscow 58
San Diego 55
Milan 51
Jacksonville 45
Helsinki 39
Redondo Beach 36
Lappeenranta 34
Nuremberg 33
Jakarta 31
São Paulo 31
London 29
Chennai 28
Toronto 27
Chicago 23
North Bergen 23
Del Norte 21
Orem 21
Seoul 21
Zhengzhou 21
Montreal 20
Salt Lake City 20
Naples 19
Brooklyn 18
Menlo Park 18
Phoenix 18
Boardman 17
Perugia 17
Redwood City 16
Atlanta 15
Colorado Springs 15
Frankfurt am Main 15
Warsaw 15
Charlotte 14
Shanghai 14
Vienna 14
Boston 13
Denver 13
Esslingen am Neckar 13
Hyderabad 13
Kraków 13
Johannesburg 12
Manchester 11
Bologna 10
Falls Church 10
Guangzhou 10
Kingston 10
Amsterdam 9
Genoa 9
Pune 9
Saint Petersburg 9
San Francisco 9
Turku 9
Ankara 8
Columbus 8
Da Nang 8
Haiphong 8
Mexico City 8
Stockholm 8
Turin 8
Asunción 7
Engelhard 7
Poplar 7
Porto Alegre 7
Rio de Janeiro 7
Bari 6
Brussels 6
Catania 6
Chengdu 6
Goiânia 6
Guiyang 6
Totale 15.313
Salva come PNG Salva come JPEG
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 539
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 466
Brodalumab for the treatment of psoriasis 460
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 426
Tildrakizumab for treating psoriasis 425
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 417
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 409
Tofacitinib for the treatment of psoriasis 405
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 404
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 401
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 398
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies 388
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 375
A safety evaluation of guselkumab for the treatment of psoriasis 375
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 374
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 358
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. 352
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 350
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 345
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 334
Photo-recall cutaneous reaction to gemcitabine 325
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 319
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 304
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 300
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 296
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 288
Pharmacotherapeutic management of psoriasis in adolescents and children 273
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 271
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 265
Skin immunity and its dysregulation in psoriasis 264
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study 258
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy 251
Successful treatment of psoriatic crumbly nails with ustekinumab 245
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 241
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 235
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 228
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 224
letter in response to the case report: “recalcitrant generalized granuloma annulare treated successfully with dupilumab” 204
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers 204
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 199
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 162
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 146
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 146
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience 140
Italian guidelines in diagnosis and treatment of alopecia areata 137
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 135
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 133
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 127
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) 126
Effectiveness of brodalumab for the treatment of moderate-to-severe psoriasis: a retrospective, real-world multicenter study with a focus on obese and multi-failure patients—IL PSO (Italian Landscape Psoriasis) 126
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 125
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 123
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 117
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients 115
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 115
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 114
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View 112
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 109
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 109
A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: The EARLY study 107
Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series 104
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 104
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks 99
BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis) 99
Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis 99
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 99
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 96
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 95
Quality of life and psychological impact in patients with atopic dermatitis 94
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 92
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 90
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 89
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 89
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab 88
HLA-C*06:02 allele can influence clinical efficacy of certolizumab pegol? 88
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks 87
Linear psoriasis following the typical distribution of the sciatic nerve 87
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 87
Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study–IL PSO (Italian Landscape Psoriasis) 86
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 86
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study 84
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study 83
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 83
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 82
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis 81
Eczematous liraglutide eruption managed by dupilumab: A case report 81
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 80
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy 80
Anti-Herpes zoster vaccination in patients with dermatologic diseases: a position statement from the Italian SIDeMaST group of sexually transmitted, infectious and tropical diseases 78
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 77
successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: a case series 76
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study 75
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 74
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry 74
A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis? 72
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice 71
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents 71
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study 70
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 69
A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis 68
Totale 19.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.510
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.510
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022746 0 0 81 14 31 35 140 34 60 52 73 226
2022/2023807 101 81 69 61 55 207 68 32 57 22 30 24
2023/2024565 33 6 15 16 45 80 93 51 3 40 120 63
2024/20252.543 101 412 246 266 49 279 108 119 238 198 315 212
2025/20264.864 293 158 578 254 359 152 627 526 565 519 370 463
2026/2027706 254 277 175 0 0 0 0 0 0 0 0 0
Totale 20.482